Afamitresgene Autoleucel & Vorasidenib

Update: 2024-08-08

Description

A new cellular therapy is approved for synovial sarcoma and the anticipated approval has occurred for the dual IDH1/IDH2 inhibitor, vorasidenib.

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

2024 New Drug Review

2024-12-1918:03

A Feast Of Updates

2024-12-1217:05

Zenocutuzumab

2024-12-0512:45

Revumenib

2024-11-2114:52

Anthracycline Use In Breast Cancer

2024-11-1409:52

SWISH

2024-11-0709:18

Zolbetuximab

2024-10-3119:30

S1826 & INTERLACE

2024-10-2422:49

Inavolisib

2024-10-1716:42

Autumnal (2024) AML Updates

2024-10-1013:48

MSI-High Rectal Cancer Treatment

2024-10-0310:03

NATALEE + a slew of FDA updates

2024-09-2616:39

ESMO 2024

2024-09-1922:17

Doxorubicin + Trabectedin

2024-09-0517:00

Chapter 1. Doses Matter

2024-08-2922:48

Cross-Trial Comparison Don'ts

2024-08-2219:31

Olanzapine For MEC

2024-08-1514:17

Afamitresgene Autoleucel & Vorasidenib

2024-08-0812:29

Perioperative ICI Trial Design & Blood Test Screening For Colorectal Cancer

2024-07-3115:47

The Auto Transplant Breast Cancer Scandal

2024-07-2515:28

00:00

1.0x

Afamitresgene Autoleucel & Vorasidenib

#box-pro-ellipsis-173491077120545{-webkit-line-clamp:2;}Afamitresgene Autoleucel & Vorasidenib

Afamitresgene Autoleucel & Vorasidenib

John Bossaer

Afamitresgene Autoleucel & Vorasidenib